{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-055286","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.608144+00:00","generated_at":"2026-05-20T02:43:44.869345+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem reports 52% ORR in PDAC and 42% ORR in NSCLC for KRAS G12D inhibitor VS-7375","bullets":["Phase 1 data from China: 23 PDAC patients had 52% ORR and 100% DCR; 12 NSCLC patients had 42% ORR and 83% DCR.","No dose-limiting toxicities observed across 100-900 mg QD; TRAEs mostly Grade 1/2; no TRAE-related deaths.","U.S. Phase 1/2a study for VS-7375 to start at 400 mg dose; plans to evaluate monotherapy and combinations in pancreatic, colorectal, and NSCLC.","Data presented at ASCO 2025; GenFleet is partner in China; Verastem holds rights in U.S. and other regions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-055286","json":"https://secwatch.observer/filing/0001104659-25-055286.json","markdown":"https://secwatch.observer/filing/0001104659-25-055286.md","text":"https://secwatch.observer/filing/0001104659-25-055286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925055286/0001104659-25-055286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925055286/tm2516844d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:43:44.869345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}